Testosterone After Hip Fracture: What This Trial Does, and Doesn’t, Show
The STEP‑HI randomized clinical trial examined whether high‑dose testosterone gel combined with supervised exercise improves recovery in women aged 65 and older after hip fracture. Participants were assigned to testosterone plus exercise, placebo gel plus exercise, or enhanced usual care for 24 weeks. The primary endpoint—six‑minute walk distance at 24 weeks—showed no advantage for the testosterone group. Secondary and post‑hoc analyses yielded isolated signals that were not consistent across comparisons, underscoring that the study does not support routine testosterone use for post‑fracture rehabilitation.
The Attention Economy of Menopause Medicine
The post highlights how three so‑called “miracle cures” for menopause brain fog—ADHD meds, creatine, and antihistamines—have surfaced within a year, exposing a medical knowledge gap that drives women to seek answers online. Social media’s attention economy amplifies sensational, unverified claims,...
Live with Dr. Jen Gunter
In this episode, host Dr. Cammy Dahl chats with Dr. Jen Gunter about Gunter's new book, *A Terrible Strength*, which explores how systemic racism and the cultural expectation of endurance among Black women lead to delayed diagnosis and higher mortality...
Antihistamines, Pepcid, and Menopause Brain Fog
Recent social‑media posts have suggested that over‑the‑counter antihistamines such as cetirizine and the acid‑blocker famotidine can alleviate menopause‑related brain fog. The author notes that no clinical or observational studies support this claim, making it a hypothesis rather than evidence‑based therapy....
CRP: What It Can, and Can't, Tell You
High‑sensitivity C‑reactive protein (hsCRP) is an inflammation marker used to refine cardiovascular risk assessment. The 2025 ACC scientific statement recommends a one‑time baseline hsCRP measurement, with values 3 mg/L high risk. Clinical trials such as JUPITER demonstrated that statin therapy reduces...
MHT and Mortality: Reassuring Data From a New Study
A new nationwide Danish cohort study of over 800,000 women examined long‑term menopausal hormone therapy (MHT) and mortality. Researchers tracked participants for an average of 14.3 years, including more than 100,000 MHT users, some with ten or more years of...
Estrogen Is Estrogen As Far As Your Uterus Is Concerned
The article challenges the common claim that transdermal, “bioidentical” estradiol is safer for the uterus than other estrogen therapies. It explains that any estrogen that activates the ERα receptor drives endometrial cell division, regardless of its source. By comparing transdermal...
Progesterone in MHT for Protection Against Endometrial Cancer
Recent analysis of menopausal hormone therapy (MHT) highlights a tension between breast‑cancer safety and endometrial risk. Observational data from France’s E3N cohort found that women using oral micronized progesterone for five or more years faced a 2.7‑fold increase in endometrial...
Live with Dr. Jen Gunter
In this episode, Dr. Jen Gunter discusses her new birth guide, emphasizing the importance of informed, autonomous decision‑making throughout pregnancy, labor, and postpartum care. She critiques outdated medical lore and highlights how misinformation, legal restrictions, and institutional biases—such as those...
The Myth of “Brain-Safe” Vaginal Progesterone
A viral claim suggests oral progesterone harms brain health while vaginal progesterone is safer for menopausal hormone therapy. The author refutes this by citing the KEEPS trial, which showed no cognitive decline or MRI changes after four years of oral...